Previous 10 | Next 10 |
LA JOLLA, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial results for the third quarter ending May 31...
Artelo Biosciences (NASDAQ: ARTL ) initiated with Buy rating and $8 (113% upside) price target at Maxim Group. More news on: Artelo Biosciences, Inc., NextCure, Inc., Apellis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
LA JOLLA, Calif., June 25, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NasdaqCM: ARTL, ARTLW) (the “Company” or “Artelo Biosciences”), a clinical-stage biopharmaceutical company with a portfolio of novel therapeutic candidates targeting the endocannabinoid...
Artelo Biosciences ( OTCQB:ARTL N/A ) has priced its public offering of ~1.3M units at $6.15/unit, for gross proceeds of $8M. More news on: Artelo Biosciences, Inc., Read more ...
LA JOLLA, Calif., June 21, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NasdaqCM: ARTL, ARTLW) (the “Company” or “Artelo Biosciences”), a clinical-stage biopharmaceutical company with a portfolio of novel therapeutic candidates targeting the endocannabinoid...
Clinical-Stage Biopharmaceutical Company Engages Financial Industry Veteran LA JOLLA, CA / ACCESSWIRE / May 8, 2019 / Artelo Biosciences, Inc. (OTCQB: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, a...
LA JOLLA, CA / ACCESSWIRE / January 3, 2019 / Artelo Biosciences, Inc. (OTCQB: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced that it has retained Maxim Group LLC (Maxim) to provide ge...
Artelo Biosciences to Be Featured On Cannabinoid Panel Discussion at LSX World Congress USA on October 11 th , 2018 LA JOLLA, CA / ACCESSWIRE / October 9, 2018 / Artelo Biosciences, Inc. (OTCQB: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeu...
LA JOLLA, Calif., July 3, 2018 /PRNewswire/ -- Artelo Biosciences, Inc. (OTCQB: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutic treatments that modulate the endocannabinoid system, today announces its sponsorship of the Young Inv...
Artelo Biosciences ( OTCQB:ARTL ) inks an R&D agreement with Bengaluru, India-based Syngene International Ltd. to develop ART27.13, a Phase 2-stage dual cannabinoid agonist, for cancer indications, including cancer-related anorexia and weight loss. More news on: Artelo Biosciences, I...
News, Short Squeeze, Breakout and More Instantly...
Artelo Biosciences Inc. Company Name:
ARTL Stock Symbol:
OTCMKTS Market:
Artelo Biosciences Inc. Website:
ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment Phase 1 trial results expected in the first half of 2025 SOLANA BEACH, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- A...
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a c...